EMulate Therapeutics
PrivateLast Round
Crowdfunding
Oct 28, 2025
Est. Valuation
$250M
Total Funding Raised
$733,267
Momentum
Top 10%
of companies Caplight tracks
Company Overview
EMulate Therapeutics operates in Healthcare & Life Sciences and is based in Bellevue, Washington. Its latest recorded funding round was a Crowdfunding round in October 2025.
EMulate Therapeutics is a healthcare company that has developed a platform using ultra-low radio frequency energy (ulRFE®) intended to provide therapeutic benefits for conditions such as cancer, pain, and mental health disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Mental Health, Clinical Trials
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EMulate Therapeutics Comparables
Compare EMulate Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Autem Therapeutics | 85% | |
| Novocure | 77% | |
| TheraBionic | 76% |
For institutional investors. Book with your work email.
EMulate Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Crowdfunding | Oct 28, 2025 | ||||
| IPO | Jul 31, 2024 | ||||
| Convertible Debt | Jul 20, 2021 | ||||
| Convertible Debt | Feb 23, 2021 | ||||
| VC Round | Feb 24, 2017 | ||||
Series A Extension | Feb 1, 2012 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
EMulate Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| E.F. Hutton & Co. | IPO |
| Brookline Capital Markets | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 334% MoM, reaching 1.9K.
- Jan 19, 2026
Monthly visitors increased 65% MoM.
For institutional investors. Book with your work email.
EMulate Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about EMulate Therapeutics's valuation, stock price, and market status.
Is EMulate Therapeutics a public or private company?
EMulate Therapeutics is a private company.
What is the current stock price of EMulate Therapeutics?
EMulate Therapeutics is a private company, so its shares have no public market price. Caplight tracks EMulate Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is EMulate Therapeutics worth (valuation)?
EMulate Therapeutics's valuation is estimated at $250.0M based on funding round data.
Can I buy EMulate Therapeutics stock?
EMulate Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was EMulate Therapeutics's last funding round?
EMulate Therapeutics's most recent funding round was Crowdfunding on October 28, 2025.
Who are the main investors in EMulate Therapeutics?
Key investors in EMulate Therapeutics include Brookline Capital Markets.
Will EMulate Therapeutics IPO soon?
No public IPO plans have been announced for EMulate Therapeutics.
How can I track EMulate Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in EMulate Therapeutics's shares on secondary markets.